Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736600 · ClinicalTrials.gov registry record · NA
Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial
A NA study of Peripheral Neuropathy Due to Chemotherapy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06736600: Recruiting NA study of Peripheral Neuropathy Due to Chemotherapy, sponsored by M.D. Anderson Cancer Center.
NCT06736600 is a NA study of Peripheral Neuropathy Due to Chemotherapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 54-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06736600, a NA study of Peripheral Neuropathy Due to Chemotherapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
A behavioral trial aimed at helping patients identify what matters most to them and is part of a larger effort to pivot from disease-oriented care to whole-person care.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- BEHAVIORAL Goal Attainment Scaling (GAS)
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-04-18 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT06736600 shows while recruiting
NCT06736600 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 54-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 1 intervention - of which Goal Attainment Scaling (GAS) is the first listed.
NCT06736600 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06736600 about?
NCT06736600 is a clinical study titled "Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial". A behavioral trial aimed at helping patients identify what matters most to them and is part of a larger effort to pivot from disease-oriented care to whole-person care.
What is the current status of trial NCT06736600?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2025-04-18. Estimated completion is 2027-08-31.
What conditions does trial NCT06736600 study?
This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy.
What interventions are being tested in trial NCT06736600?
The interventions under investigation include: Goal Attainment Scaling (GAS) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06736600?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736600 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Neuropathy Due to Chemotherapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
RECRUITING · NA
-
Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)
RECRUITING · NA
-
Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study.
RECRUITING · NA
-
Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
RECRUITING
-
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
RECRUITING · Early Phase 1
-
Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI